



Supplementary Fig. 5. Feladilimab induces phospho-AKT in ICOS-expressing Ba/F3 cells and cytokine production in PBMC from healthy donors and cancer patients. (a, b) Ba/F3 (mouse) cells with or without expression of human ICOS (Ba/F3-huICOS) were treated with feladilimab (20 μ g/ml) for 1 hour and assessed for changes in AKT phosphorylation. ICOS expression was readily detectable in both wild-type and Ba/F3-huICOS cells using a polyclonal human-mouse cross-reactive antibody (ab133680). **(a)** and **(b)** show data from two independent experiments; gels are cropped, uncropped gel images are available in **Supplementary Fig. 4 b, c**. **(c, d)** cytokine production in the supernatant of

PBMC cultures from **(c)** healthy donors and **(d)** NSCLC patients following stimulation with feladilimab and anti-CD3 (24 and 48 hours for healthy donors; 72 hours for NSCLC patients) (data representative of 3 independent experiments using PBMC from 3 different donors).

Individual values are shown in **(c, d)**, with bars representing the mean \pm s.e.m.